Miami, FL (November 18, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/II clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Proteintech and HebeCell to Collaborate on Nanobody iPSC-derived NK Cells
CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases. [Read more…]
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
– FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology
– The agreement enables drug developers to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements
Organicell Provides Update on Its COVID-19 Clinical Trial Using Zofin™
-
Anticipates Phase I/II trial completion by end of year
-
Anticipates Phase IIb trial to begin in Q1 2021
-
Seeks to retain a global contract research organization (“CRO”)
Miami, FL (November 12, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for treatment of COVID-19 using Organicell’s proprietary therapeutic, Zofin™, which is currently underway as well as an update on its expanded access protocol for outpatients with COVID-19. [Read more…]
Trailhead Biosystems Raises $6.6 Million in Series A Financing
Therapeutic cell pioneer Trailhead Biosystems raises Series A funding for development of specialized human cells
Financing will expand the company’s High Dimensional Design of Experiments platform (HD-DoE), support the generation of multiple specialized human cells with therapeutic properties and their pilot scale manufacturing
CLEVELAND, Ohio, November 10th, 2020. Trailhead Biosystems Inc. (www.trailbio.com) – a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology – announced its $6.6 million Series A financing. The company has developed a proprietary platform to perform systems-level interrogation of complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies. [Read more…]
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 123
- Next Page »